Scynexis Inc

+0.06 (+2.47%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)90.93M
Current PEN/A
Forward PE 4.02
2yr Forward PE 1.84
See more stats
Estimates Current Quarter
Revenue$90.4 Million
Adjusted EPS$1.35
See more estimates
10-Day MA$2.55
50-Day MA$2.91
200-Day MA$2.26
See more pivots

Scynexis Inc Stock, NASDAQ:SCYX

1 Evertrust Plaza, 13th floor, Jersey City, New Jersey 07302-6548
Phone: +1.201.884.5485
Number of Employees: 36


SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.